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Abstract. A number of genetic loci associate with early onset Alzheimer’s disease (EOAD); however, the drivers of this
disease remains enigmatic. Genome wide association and in vivo modeling have shown that loss-of-function, e.g., ABCA7,
reduced levels of SIRT1 and MEFF2C, or increased levels of PTK2 confer risk or link to the pathogenies. It is known
that DNA methylation can profoundly affect gene expression and can impact on the composition of the proteome; therefore,
the aim of this study is to assess if genes associated with sporadic EOAD (sEOAD) are differentially methylated. Epi-
profiles of DNA extracted from blood and cortex were compared using a pyrosequencing platform. We identified significant
group-wide hypomethylation in AD blood when compared to controls for 7 CpGs located within the 3’UTR of RIN3
(CpG1 p = 0.019, CpG2 p = 0.018, CpG3 p = 0.012, CpG4 p = 0.009, CpG5 p = 0.002, CpG6 p = 0.018, and CpG7 p = 0.013,
respectively; AD/Control n = 22/26; Male/Female n = 27/21). Observed effects were not gender specific. No group wide
significant differences were found in the promoter methylation of PTK2, ABCA7, SIRT1, or MEF2C, genes known to
associate with late onset AD. A rare and significant difference in methylation was observed for one CpG located upstream
of the MEF2C promoter in one AD individual only (22% reduction in methylation, p = 2.0E-10; Control n = 26, AD n = 25,
Male/Female n = 29/22). It is plausible aberrant methylation may mark sEOAD in blood and may manifest in some individuals
as rare epi-variants for genes linked to sEOAD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neu-
rodegenerative condition and the leading cause of
dementia among the elderly [1]. AD can segment
into two classifications depending on age at diagno-
sis, raising the possibility of different initiators of
disease for each group. Late onset AD (LOAD) is the
most prevalent form, a condition which affects those
over the age of 65 and accounts for approximately
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90 to 95% of all those diagnosed with AD. Early
onset AD (EOAD) typically affects those under the
age of 65 and is much rarer, accounting for just 5%
to 10% of all AD cases [2].
The genetic explanation for LOAD is complex
with a growing number of different genes impli-
cated, reviewed by [3], yet none in isolation fully
accounts for disease susceptibility. EOAD however
can be sub-divided into two groups, familial and spo-
radic. Familial AD (fAD) is thought to be easier to
explain, driven by mutations within a growing list
of different genes, including but not limited to amy-
loid protein precursor (APP) or presenilin (PSEN1
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and PSEN2) genes [2, 4]. Sporadic EOAD (sEOAD),
although like fAD occurs in individuals under the
age of 65, has proven much harder to pin to any one
gene or pathway. Comparative transcriptomic anal-
ysis of sEOAD and fAD brain tissue identified over
3000 differentially expressed genes [5], suggesting
sEOAD and fAD may be distinct neurodegenerative
processes.
An increasing number of genes link with LOAD, an
association identified through comparative genome
wide association data analysis (GWAS) [6]. These
new studies link numerous pathways to pathogenesis,
correlating genes and cellular processes not previ-
ously considered relevant [6]. Current models suggest
LOAD may be a complex multifactorial condition
driven by a number of different genes located within
independent pathways [3]. Although each genetic
variant links to disease, frequency within the wider
population can vary; even the most common LOAD
risk APOE 4 allele only presents in 40% of LOAD
patients. Diversity in the frequency of genetic drivers
of AD may be considered surprising given the sim-
ilarities in the pathology of the disease collectively
among AD sufferers. One plausible hypothesis is that
these genes could be differentially regulated within
groups of AD suffers, existing within the popula-
tion as variants at an epigenetic or regulatory level.
Some data exists to support this notion. Differences
in DNA methylation of AD associated genes have
been identified in DNA samples taken from both
the blood and the brain of patients diagnosed with
LOAD [7–12]. Notably APP has been found to be
differentially methylated within the promoter region
in LOAD, while sirtuin1 (SIRT1) has been shown to
be differential methylated in a Chinese AD popu-
lation [13–15]. Little, however, is currently known
about the epigenetic status of genes that associate
with sEOAD.
Stable changes in DNA methylation can be induced
by a person’s lifestyle or environment and may
progressively accumulate over many years. Levels
of methylation may direct gene expression lead-
ing to changes in the levels of proteins, which
may cause, drive, or exacerbate AD disease symp-
toms [16, 17]. Initial epi-profiling already undertaken
using LOAD samples suggests this hypothesis may
be correct for later onset AD [7]; however, little
work to date has been undertaken to investigate
any putative epigenetic link with sEOAD. We there-
fore sought to investigate if those LOAD genes
genetically associated with AD occur as epi-variants
in sEOAD.
Genes previously associated with LOAD
through GWAS profiling are likely candidates for
epi-profiling with variation encoded by methylation.
Genes already profiled using genetic association
with LOAD include but are not limited to PTK2,
ABCA7, and MEF2C [18]. These three genes are
all implicated in a range of pathways associated
with AD pathology. PTK2 functions in memory
formation and cell proliferation and survival [19, 20],
ABCA7 has a role in regulating APP processing
and inhibiting amyloid- [21–23], while MEF2C is a
transcription factor involved in preventing excessive
synapse formation [24].
Another gene, a candidate target of interest for both
genetic and epigenetic analysis, is SIRT1. This gene
is functionally implicated in AD disease pathology in
a number of studies [25–28]. Disease linked differen-
tial methylation of a non-coding region of SIRT1 has
already been demonstrated in peripheral blood leuko-
cytes of a Chinese LOAD population [13], therefore
a comparative approach investigating sEOAD could
be informative. Previous research by Hou et al. [13]
identified two CpGs outside of the promoter CpG
Island (CGI) to be significantly hypermethylation
in LOAD samples; this suggests that epi-profiling
should not just be restricted to CpG repeats, explor-
ing the wider gene region may reveal interesting
information around regulation linked to disease.
There is some evidence to suggest that investigat-
ing regulatory features other than the promoter region
could be productive. A 3’UTR CGI found within
the RIN3 gene is located on chromosome 14 and
sits between two AD associated genes SLC24A4 and
LGMN [18]. RIN3 is interesting in isolation as this
gene associates with AD pathology through its inter-
action with BIN1, a gene that shows the second most
significant LOAD score after APOE [29]. Further it
has also been found to be differentially methylated in
LOAD [8]. It is likely that BIN1 and RIN3 interact in
the process of endocytosis negatively effecting amy-
loid trafficking [30, 31]. Since 3’ UTR methylation
has recently emerged as an important epigenetic mark
influencing gene expression, transcriptional elonga-
tion and splicing it is a valid hypothesis that this CGI
may represent an informative target for epi-profiling
[32–34].
To date most transcriptomic or proteomic analy-
sis is conducted using brain tissue. While profiles
obtained from brain material may be informative
about the direct epigenetic consequences of AD
pathology, this tissue it is not a viable source for
the identification of new biomarkers. Also it is well
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established that brain methylation can differ signifi-
cantly between the different regions of the brain [12].
Additional technical limitations include a restriction
on test subject numbers through limited availabil-
ity of tissue. Interestingly leukocytes are thought to
acquire epigenetic markers linked to disease as they
transit through the afflicted tissue. In limited studies
to date, peripheral blood DNA methylation has been
shown to be representative of brain methylation [35].
Blood based epigenetic biomarkers may be a use-
ful addition to the AD diagnostic tool kit available,
while also informing on the fundamental biology of
sEOAD.
This study profiles comparative levels of methyla-
tion present in individuals presenting with sEOAD.
Through profiling DNA extracted from both blood
and brain, we have identified variation in the methy-
lation of key genes that may link to AD and the
progression of sEOAD. Differences in methylation
may be consistent across many CpGs or could be
restricted to a single bp.
MATERIALS AND METHODS
DNA samples
sEOAD DNA samples were obtained from the
Alzheimer’s Research UK Consortium DNA Bank,
a resource curated by the University of Nottingham
and were either extracted from leukocytes (n = 51) or
brain (cortex) (n = 24). In total 40 sEOAD and 21
control samples were used. 25 blood and 14 cor-
tex brain AD samples and 26 blood and 10 brain
control samples were used (See Table 1 for further
information). DNA samples used in this study have
been genetically tested by Alzheimer’s Research UK
Consortium DNA Bank and none contained fAD
mutations.
All samples used in this study were received with
informed consent and experimental procedures were
approved by the local ethics committee, Notting-
ham Research Ethics Committee 2 (REC reference
04/Q2404/130). All experimental procedures were
conducted in accordance with approved guidelines.
DNA extraction
Approximately 200 mg of cortex tissue was
chopped finely on dry ice then transferred to a 1.5 ml
Eppendorf tube. This was then incubated overnight
(∼18 h, shaking at 380 rpm, 50◦C) with 500l AL
lysis buffer and 50l proteinase K (both Qiagen) and
10l RNase A. Next, 500l of refrigerated phenol
chloroform was added to the sample (Sigma), which
was mixed by inverting before being subjected to cen-
trifugation for 5 min at 13,000 rpm. The top phase of
the resultant sample was then removed to a clean lock
phase-gel 2 ml Eppendorf, and the addition of phe-
nol chloroform, mixing and centrifugation repeated.
The top phase of this was removed, and has 3 M
sodium acetate (pH 5.2) added to it in a 1 : 9 ratio of
sodium acetate to the sample. Chilled 100% ethanol
was then added, at an equal volume to the sample,
to precipitate out the DNA. Following centrifuga-
tion at 13,000 rpm for 15 min, a wash was performed
using 500l 70% ethanol, before another centrifu-
gation step, for 15 min (13,000 rpm). The remaining
ethanol was then discarded and the pellet air-dried,
before resuspension in 100l 1xTE buffer, by heating
to 50◦C for 1 h.
Bisulphite treatment
First DNA was bisulphite-treated using the Epi-
Tect Bisulphite Conversion Kit (Qiagen, Germany),
following the manufacturer’s instructions. Bisulphite
treatment converted any non-methylated cytosines
to uracil; therefore, in the following PCR product,
non-methylated cytosines became thymine, allowing
pyrosequencing of the PCR product to result in iden-
tification of cytosine methylation. 500 ng of genomic
DNA was bisulphite-treated for each patient sample
and 10 ng of converted DNA was used in subsequent
PCRs.
In silico methods
Target regions were identified using the UCSC
Genome Browser (University of California, Santa
Cruz,CA,USA) (http://www.genome.ucsc.edu/index).
Table 1
Shows clinical features of AD and control samples
Group Sex M/F Age at death Age at onset of disease Age at sampling
Blood AD 17/8 57.95 (SD 3.28) 48.6 (SD 2.98) 47.2 (SD 2.28)
Control 13/13 N/A N/A 82.8 (SD 4.5)
Brain AD 4/10 59.35 (SD 6.95) 48.85 (SD 3.32) 59.35 (SD 6.95)
Control 6/4 84.2 (SD 3.55) N/A 84.2 (SD 3.55)
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Pyrosequencing primers were then designed for
these regions using the PyroMark Assay Design soft-
ware version 2.0 (Qiagen) and obtained from Eurofins
MWG. Pyrosequencing assays were designed using
the PyroMark Q24 software.
Polymerase chain reaction (PCR)
PCRs were conducted using the PyroMark PCR
Kit (Qiagen, Germany) following manufactures
instructions. PCRs contained 12.5l PyroMark PCR
Mastermix 2x (Qiagen), 2.5l CoralLoad Concen-
trate 10x (Qiagen), 0.25 ng of each PCR primer,
and 10 ng DNA, made up to 25l with RNase-
free water. Details of PCR primers can be found in
Supplementary Table 1; all PCR primer pairs con-
tained a biotinylated primer to result in a biotinylated
PCR product which could be captured by sepharose
coated beads during pyrosequencing. PCR programs
varied depending on primers used; details can be
found in Supplementary Table 2. PCR product qual-
ity was assessed by running 5l of PCR product on
a 1% agarose gel prior to pyrosequencing.
Pyrosequencing
A pyrosequencing platform Q24 pyrosequencer
(Qiagen, Germany) with PyroMark Gold Q24
Reagents (Qiagen, Germany) was used to determine
percentage methylation. Pyrosequencing was carried
out following manufacturer’s instructions/protocol.
Pyrosequencing results were interpreted using the
PyroMark Q24 software.
Statistical analysis
For all the methylation percentage data, one-way
analyses of variance were used to test the blood and
brain tissue data for differences between the AD and
control groups of subjects. Each of the cytosines were
analyzed separately as were the blood and brain tissue
data sets. When multiple values were recorded for
the same cytosine from the same subject, the values
were averaged to produce one value per person for
each cytosine. These averages were then analyzed
using the Analysis of Variance routines within the
Genstat18 statistical package.
The residuals from each analysis were plotted to
check the assumptions of normality and homogene-
ity of residuals, and also to highlight possible rare
variants. For rare variants, the probability of obtain-
ing residual values as, or more, extreme than the one
observed was calculated from the standard normal
distribution curve. To achieve this, the residual devi-
ation between the individual outlier and the mean
of its group; and the overall standard deviation from
the rerun analysis were used as input to the Genstat
Normal probability distribution routine.
RESULTS
PTK2β, ABCA7, SIRT1, and the MEF2C
promoter CGI showed no signiﬁcant methylation
in AD
PTK2, ABCA7, and MEF2C: Promoter regions
of AD candidate genes PTK2, ABCA7, MEF2C,
and SIRT1 were chosen as targets for analysis (see
Supplementary Table 1 and Supplementary Figure 1);
initial gene targets were selected based on previously
published GWAS risk analysis data [18] or in the
case of SIRT1, published promoter methylation data
[13]. Previous research identified PTK2, ABCA7,
and MEF2C to be associated with LOAD through
GWAS [18, 36]; however, to date few experiments
have investigated the contribution of these genes to
sEOAD. These genes may be considered prime can-
didates for regulation via an epigenetic mechanism;
therefore, we first chose to profile methylation at
these loci in blood and brain tissue taken from sEOAD
patients.
For PTK2, ABCA7, and MEF2C, the CpG island
closest to the start site of transcription was chosen
for analysis (details in Supplementary Figures 1 and
2). In total, we profiled 5, 8, and 4 CpGs for PTK2,
ABCA7, and MEF2C, respectively; however, unex-
pectedly, we failed to detect any significant difference
in the average regional level of methylation across
genes investigated in sEOAD blood or brain derived
samples (Fig. 1) (p > 0.05). It is interesting to note that
forPTK2,ABCA7, andMEF2C, the regions targeted
showed relatively low average levels of methylation
in cortex and blood tissue of both AD and control
samples.
Given the absence of variation we observed for
PTK2, ABCA7, and MEF2C, we opted to profile
levels of methylation at an AD linked loci previ-
ously reported to be differentially methylated [13].
SIRT1 associates with AD pathology through its role
in attenuating A toxicity and preventing tau cytotox-
icity [25–28]; therefore, it is reasonable to suggest
aberrant methylation may impede this protective
effect. As this previous study was undertaken using
samples obtained from LOAD patients, we chose
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Fig. 1. Box plots showing data representing average methylation across the regions investigated for PTK2 (A), ABCA7 (B), SIRT1 (C), and
the MEF2C promoter CGI (D). No significant difference in methylation was observed between AD and control in either blood or brain tissue.
Box plots represent median with 25th and 75th percentile as edges, the whiskers either show the lowest and highest values or extend to the
first quartile minus the interquatile range multiplied by 1.5 and up to the third quartile add the interquartile range times 1.5, depending on
which values are largest or smallest (for the top and bottom whiskers respectively). For PTK2 control blood n = 6, AD blood n = 5, control
brain n = 3, and AD brain n = 4. For ABCA7 control blood n = 7, AD blood n = 4, control brain n = 3, AD brain = 6. For SIRT1 control blood
n = 4, AD blood n = 5, control brain n = 3, and AD brain n = 3. For the MEF2C CGI region Control blood n = 3, AD blood n = 5, Control brain
n = 3, AD brain n = 4.
to investigate if the epigenetic variation previously
reported could also be observed in sEOAD patients.
In order to directly compare levels of methylation
for our sEOAD sample library with a previously
published candidate AD associated epi-loci, we pro-
filed two CpGs reported to be hypermethylated in
LOAD peripheral blood [13]. Where tested, we found
no significant difference in methylation compared to
controls at either CpG site in blood.
Methylation at the resolution of individual CpGs
We detected no difference in the average regional
level of methylation for each of the four candidate
genes tested and no significant difference in methy-
lation was identified for any individual CpG
duplet within CpG islands upstream of ABCA7,
SIRT1 or MEF2C in either tissue (p > 0.05; Sup-
plementary Figure 3). However, interestingly, one
specific CpG site investigated within the PTK2
promoter CGI showed significant hypermethyla-
tion in AD blood (p = 0.04) but not AD cortex
(p = 0.47) (Fig. 2). The average methylation found
at CpG1 in AD blood was 8.4% compared to 5%
in control blood. Although statistically significant,
and all samples were completed in duplicate, it
should be noted that this difference is relatively
small [37].
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Fig. 2. PTK2 shown at resolution of individual CpG: For the target region investigated in the PTK2 promoter CpG1 was found to be
significantly hypermethylated in AD Blood but not AD brain. Average methylation at each CpG investigated in controls (white bar) and AD
(black bar) in blood (A) and brain (B) is shown, error bars represent S.E.M. ∗p < 0.05 (one tailed T-test). For blood control n = 6 AD = 5, for
brain control n = 3, AD n = 4.
MEF2C Epi-variant CpG upstream of promoter
CGI investigated
CpGs located within the CpG island upstream of
the transcription start site of MEF2C(1), (see Fig. 3),
show equivalent levels of methylation between AD
and control samples. However, it is plausible that
methylation located at other upstream CpGs outside
of this location may be crucial in determining either
levels of transcription or the structure of the transcript
expressed, therefore a further CpG site was targeted
(shown asMEF2C(2) in Fig. 3). As a group wide aver-
age, there was no evidence of a difference between the
AD and control groups in either the blood (p = 0.708)
or cortex (p = 0.593) data set (Fig. 3). Average lev-
els of methylation were substantially higher than
those of the other genes tested; average methyla-
tion of 91% in blood and 86% in brain average. No
significant difference in methylation was observed
between the tissue types (p > 0.05) (Supplementary
Figure 4).
Intriguingly however, we identified a difference in
methylation at this CpG in one AD patient blood sam-
ple only (Fig. 4). The probability of observing, by
chance, a value as low or lower than 70 for the AD
group in the blood data was calculated using one-way
analyses of variance 2.0E-10. Average methylation at
the CpG of 70% was recorded for the individual M341
(blood sample). This represented a 22% reduction in
methylation when compared to average methylation
in blood at this site in the other samples tested (total
n = 51). Average methylation was calculated using
data obtained from at least two technical repetitions
in order to exclude the possibility of a technical error.
It is established that rare genetic differences within
this gene can be associated with sEOAD, it could be
suggested that rare epigenetic variation at this site
may also associate as a risk factor.
In order to eliminate the possibility of a genetic
cause of the methylation observed in this exper-
iment, samples were genotyped for the published
GWAS SNP; no association with this genotype was
found.
RIN3 3’UTR showed signiﬁcant hypomethylation
in AD blood but not AD brain
RIN3 has been proven to interact with the AD
associated protein BIN1, which in turn has also
been significantly associated with AD via GWAS.
This gene has also been shown to be differentially
methylated in LOAD with an established link to AD
pathology [8, 9, 38]. We chose to investigate a CpG
island identified within the 3’UTR of RIN3 (see Sup-
plementary Table 1 and Supplementary Figure 2).
Pyrosequencing covered seven CpGs in total within
this region (shown in Supplementary Figure 2) and
average levels of methylation was calculated for AD
blood, control blood, AD brain, and control brain
(Fig. 5) across all seven CpGs tested. AD blood
samples showed hypomethylation when compared to
control blood (see Fig. 5).
For each of the cytosines CPG1-7 data (Fig. 6) from
the blood samples, there was a significant difference
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Fig. 3. (A) Diagram showing the location of MEF2C(1) and MEF2C(2) targets within the MEF2C gene. (B) In terms of the second region
of MEF2C investigated no obvious collective group wide differences between Control and AD at this CpG site were observed. Box plots
shows median with 25th and 75th percentile as edges, the whiskers extend to the first quartile minus the interquatile range multiplied by 1.5
and up to the third quartile add the interquartile range time 1.5. Control blood n = 26, AD blood n = 25, Control brain n = 10, AD brain n = 14.
between the AD and control group in %methylation
(p < 0.05) (CpG1 p = 0.019, CpG2 p = 0.018, CpG3
p = 0.012, CpG4 p = 0.009, CpG5 p = 0.002, CpG6
p = 0.018 and CpG7 p = 0.013, respectively); the AD
group being lower than the control for all CPG 1–7
and there were no extreme outliers. The p values
from the analyses were also compared to Bonfer-
roni adjusted critical p values of 0.05/7 = 0.007 to
adjust for the fact that 7 CGP data-sets were analyzed
separately from each individual. CpG5 retained sig-
nificance (p = 0.002) after strict Bonferroni correction
for multiple comparisons, suggesting that aberrant
methylation is centered within this region and spreads
outwards across neighboring CpGs.
There was no evidence (p > 0.05) of a difference
between groups in % methylation for any of the
cytosines CPG1-7 from the brain samples. Average
methylation across this region in control blood was
47.8% while average methylation in AD blood was
37.29% a reduction of 10%. No significant differ-
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Fig. 4. (A) Methylation profiling identifies rare individual AD hypomethylation of the upstream MEF2C CpG site. Patient sample M341
showed statistically significant difference in methylation (p = 2.0E-10) when compared to other blood samples (A), statistical significance
was not observed for patient M715 in brain (B). A) Shows average methylation at the CpG investigated in each sample investigated (average
of at least two runs). Controls are shown in white and AD samples in black. Error bars represent the S.E.M. Control blood = 26, AD blood
n = 25, control brain n = 10, AD brain n = 14; Male brain n = 10, Female brain n = 14, Male blood n = 29 0, Female blood n = 22.
ence in average methylation was detected between
AD brain and control brain. No link with gender
was identified for overall levels of methylation at the
RIN3 site; no aggregate difference could be detected
between male and female samples for either blood or
brain (see Supplementary Figure 6).
Tissue speciﬁc hypomethylation was observed in
AD brain
Having established that in some instances com-
parative regional differences in methylation may be
specific to AD patients, we chose to compare rela-
tive levels of methylation between tissues tested in
this study. No significant difference in methylation
was observed between tissues in either control or
AD samples (Supplementary Figure 5) for AD and
Control PTK2 (p = 0.42; p = 0.1), ABCA7 (p = 0.43;
p = 0.46), SIRT1 (p = 0.06; p = 0.24), and MEF2C(1)
(p = 0.33; p = 0.37) (these are the p values using one-
tailed T-tests, two tailed are, for AD and control
PTK2 (p = 0.85: p = 0.2), ABCA7 (p = 0.87; p = 0.9),
SIRT1 (p = 0.13; p = 0.49), and MEF2C(1) (p = 0.66;
p = 0.73). However, within the RIN3 3’UTR region
of blood DNA was significantly hypermethylated
in both AD and control blood when compared to
AD and control brain (Supplementary Figure 7).
Hypomethylation was also observed in brain tis-
sue for the MEF2C(2) site tested (Supplementary
Figure 4).
DISCUSSION
Much resource has been committed to inves-
tigating the pathogenesis of LOAD, however a
comprehensive understanding of sEOAD has thus far
remained elusive; it is likely that new ways of under-
standing drivers of sEOAD are required. Although
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a number of genes have been identified as drivers or
causal to LOAD and fAD, those genes and associated
pathways do not necessarily explain the underlying
causes of sEOAD. We propose that aberrant epige-
netic regulation contributes at least in part to this
process for some individuals. Uncontrolled or dys-
regulation of a number of varied gene pathways or
processes has been implicated in neurodegeneration;
therefore, it is plausible that aberrant regulation of
one of many genes may exacerbate pathogenesis [5].
Methylation of the SIRT1 promoter in LOAD
patient samples has been previously reported by Hou
et al. [13]; we therefore chose to test if equivalent
Fig. 5. Collective group wide methylation Control versus AD for
RIN3. Graph shows average methylation across the whole region
investigated in the RIN3 3’UTR. Control blood n = 26, AD blood
n = 22, Control brain n = 10, AD brain n = 14. Control blood Male
to Female n = 12/14, AD blood Male to Female n = 15/7.
methylation could also be detected in sEOAD sam-
ples. It could be suggested that due to the core
similarities of disease progression between AD sub-
types, any epigenetic markers which are a feature of
LOAD would be matched in sEOAD. Surprisingly
we found no evidence of variation in levels of methy-
lation between sEOAD samples and controls. This
suggests that the methylation directed regulation of
SIRT1 is not impaired in the process of sEOAD, and
the sEOAD epigenome is distinct from LOAD in
at least some instances. It is not obvious how this
difference impacts on the development of sEOAD,
although given the role of SIRT1 in attenuating tox-
icities of both tau and amyloid it is likely to have
some influence on the progression of disease. Further
research is required to investigate the consequence of
SIRT1 regulation in both conditions.
Within our test group, we identified that the
gene MEF2C was significantly hypomethylated in
comparison to controls for only two individuals
presenting with sEOAD. As an aggregate no group-
wide differences could be detected, however we
observed two individuals with pronounced differ-
ences in methylation within a key regulatory region
of this gene (22% and 15% lower in blood and
brain, respectively). The aberrant epigenetic marks
recorded for this gene in this study may represent
an example of a rare epi-variant risk factors exist-
ing within the population that accentuates the risk of
developing sEOAD. Changes in epialleles can occur
as very rare events within large populations and can
have profound effects on morphology or phenotype
[39]. It is therefore a valid hypothesis to suggest that if
the expression of the affected gene links with disease
Fig. 6. RIN3 Blood and Brain; resolution of each CpG. All of the seven CpG sites investigate in RIN3 were shown to be significantly
hypomethylated in AD blood (A) but not brain (B). Showing average methylation found at each CpG site in the RIN3 3’UTR. Control shown
as a white bar (blood n = 26, brain n = 10) and AD (blood n = 22, brain n = 14) shown as a black bar. Error bars represent S.E.M.
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pathogenesis and levels of methylation controlling
expression are altered, then this change methylation
can alter the risk at the level of the individual however
infrequently this may occur within a population. We
evaluated the possibility that methylation at this site
correlates with a known genetic risk factors however
upon analysis hypomethylation did not correlate to
this particular genotype.
Where tested, we observed group wide differences
in the levels of promoter methylation at the RIN3
locus between sEOAD and control samples. Intrigu-
ingly statistically significant differences in the levels
of methylation were not limited to one CpG, but span
a number of CpGs located within this region. The
group-wide nature of these epi-polymorphisms sug-
gests that the condition of sEOAD leads to changes
in methylation at the RIN3 locus rather than being
a rarer spontaneous causative driver of disease. The
equivalence in both tissue samples also supports this
hypothesis, e.g., it is likely that the levels of methyla-
tion identified in leukocyte DNA are reflective of AD
pathology experienced as these cells transit through
the brain. Methylation of these sites is therefore
likely driven by the environment of the diseased tis-
sue, rather than methylation being causative of the
disease.
The consequence of changes in the levels of methy-
lation located with the 3’UTR of RIN3 is unclear.
RIN3 is known to associate with BIN1 and links
with the process of endocytosis and A process-
ing; therefore, it is plausible that any change that
impacts on regulation could exacerbate the progres-
sion of AD. One hypothesis is that the AD brain ramps
up the production of RIN3 in response to the amy-
loid environment via demethylation of the 3’UTR
region; increased methylation within 3’UTRs asso-
ciates with reduced expression in reporter assay tests
[33]. This is supported by the relative hypomethyla-
tion we observed in AD brain relative to blood. This
may suggest a direct correlation between the length
of exposure to the amyloid environment and levels
of methylation for RIN3. Further experiments will
be required to determine the consequence of 3’UTR
methylation on levels of gene expression and ulti-
mately to sEOAD pathogenesis.
Our data suggests that differences in methylation
may mark the development of sEOAD. Epigenetic
regulation of regions other than promoters can be
aberrantly methylated in sEOAD patients promoting,
initiating or driving AD pathology, suggesting that
changes in epigenetic marks are a feature of the devel-
opment of sEOAD. The ability to detect variations in
blood allows for the testing of a large numbers of
blood samples to further explore this hypothesis; an
option not available if the effects manifest only in the
brain epi-genome.
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